Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Alexandra Savova

Biographic Data

ID10015176
NAMEAlexandra Savova
GIVEN NAMESAlexandra
FAMILY NAMESavova
SIGNATURESAVOVA A
AFFILIATIONSMedical University of Sofia
ORCID0000-0003-4579-5524
VERIFIEDYes
TOTAL WORKS3
TOTAL CITATIONS0
WORKS AS AUTHOR3
WORKS AS EDITOR0
FIRST PUBLICATION YEAR2020
LATEST PUBLICATION YEAR2023
H-INDEX0
  • Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment

    Open Access•Antal Zemplényi, Konstantin Tachkov et al.•ARTICLE•Frontiers in Public Health•2023

    Background: Artificial intelligence (AI) has attracted much attention because of its enormous potential in healthcare, but uptake has been slow. There are substantial barriers that challenge health technology assessment (HTA) professionals to use AI-generated evidence for decision-making from large real-world databases (e.g., based on claims data). As part of the European Commission-funded HTx H2020 (Next Generation Health Technology Assessment) …

  • Recommendations for patient involvement in health technology assessment in Central and Eastern European countries

    Open Access•Ivett Jakab, Maria Dimitrova et al.•ARTICLE•Frontiers in Public Health•2023

    Introduction: Meaningful patient involvement in health technology assessment (HTA) is essential in ensuring that the interests of the affected patient population, their families, and the general public are accurately reflected in coverage and reimbursement decisions. Central and Eastern European (CEE) countries are generally at less advanced stages of implementing HTA, which is particularly true for patient involvement activities. As part of the …

  • Comparison of Cardiovascular Medicines Prices in Four European Countries

    Open Access•Zornitsa Mitkova, Mariya Vasileva et al.•ARTICLE•Frontiers in Public Health•2020

    The aim of the current study was to compare pricing methodologies at the manufacturer, wholesale, and retail levels, and to estimate the price differences of AT1-receptor blockers (sartans), Angiotensin-converting enzyme (ACE)-inhibitors, and their fixed-dose combinations (FDCs) in four countries using similar methodologies: Slovakia, Greece, Bulgaria, and Romania (SK, GR, BG, and RO, respectively). The methodologies for manufacturer, wholesale, …

No prominent works on this page.

  • Comparison of Cardiovascular Medicines Prices in Four European Countries

    Open Access•Zornitsa Mitkova, Mariya Vasileva et al.•ARTICLE•Frontiers in Public Health•2020

    The aim of the current study was to compare pricing methodologies at the manufacturer, wholesale, and retail levels, and to estimate the price differences of AT1-receptor blockers (sartans), Angiotensin-converting enzyme (ACE)-inhibitors, and their fixed-dose combinations (FDCs) in four countries using similar methodologies: Slovakia, Greece, Bulgaria, and Romania (SK, GR, BG, and RO, respectively). The methodologies for manufacturer, wholesale, …

  • Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment

    Open Access•Antal Zemplényi, Konstantin Tachkov et al.•ARTICLE•Frontiers in Public Health•2023

    Background: Artificial intelligence (AI) has attracted much attention because of its enormous potential in healthcare, but uptake has been slow. There are substantial barriers that challenge health technology assessment (HTA) professionals to use AI-generated evidence for decision-making from large real-world databases (e.g., based on claims data). As part of the European Commission-funded HTx H2020 (Next Generation Health Technology Assessment) …

  • Recommendations for patient involvement in health technology assessment in Central and Eastern European countries

    Open Access•Ivett Jakab, Maria Dimitrova et al.•ARTICLE•Frontiers in Public Health•2023

    Introduction: Meaningful patient involvement in health technology assessment (HTA) is essential in ensuring that the interests of the affected patient population, their families, and the general public are accurately reflected in coverage and reimbursement decisions. Central and Eastern European (CEE) countries are generally at less advanced stages of implementing HTA, which is particularly true for patient involvement activities. As part of the …

Business (3 works) · Medicine (3 works) · Health care (2 works) · Health Systems, Economic Evaluations, Quality of Life (2 works) · Health technology (2 works) · Political science (2 works) · Public relations (2 works) · Reimbursement (2 works) · Artificial Intelligence in Healthcare and Education (1 work) · Biomedical Ethics and Regulation (1 work)

Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae